CR9144A - Formulaciones de benzoxazoles sustituidos - Google Patents

Formulaciones de benzoxazoles sustituidos

Info

Publication number
CR9144A
CR9144A CR9144A CR9144A CR9144A CR 9144 A CR9144 A CR 9144A CR 9144 A CR9144 A CR 9144A CR 9144 A CR9144 A CR 9144A CR 9144 A CR9144 A CR 9144A
Authority
CR
Costa Rica
Prior art keywords
benzoxazols
formulations
substituted
substituted benzoxazols
Prior art date
Application number
CR9144A
Other languages
English (en)
Inventor
A Provost James
I Armstrong Trevor
B Shafi Zerina
S Tesconi Marc
Sherry Ku Mannching
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9144A publication Critical patent/CR9144A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR9144A 2004-12-02 2007-05-23 Formulaciones de benzoxazoles sustituidos CR9144A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63237504P 2004-12-02 2004-12-02

Publications (1)

Publication Number Publication Date
CR9144A true CR9144A (es) 2007-11-23

Family

ID=36565706

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9144A CR9144A (es) 2004-12-02 2007-05-23 Formulaciones de benzoxazoles sustituidos

Country Status (22)

Country Link
US (1) US20060121110A1 (es)
EP (1) EP1850833A2 (es)
JP (1) JP2008521919A (es)
KR (1) KR20070089921A (es)
CN (1) CN101128188A (es)
AR (1) AR053653A1 (es)
AU (1) AU2005311823A1 (es)
BR (1) BRPI0518786A2 (es)
CA (1) CA2589033A1 (es)
CR (1) CR9144A (es)
GT (1) GT200500349A (es)
IL (1) IL183393A0 (es)
MX (1) MX2007006564A (es)
NI (1) NI200700139A (es)
NO (1) NO20072636L (es)
NZ (1) NZ555395A (es)
PE (1) PE20061083A1 (es)
RU (1) RU2007120253A (es)
SV (1) SV2006002317A (es)
TW (1) TW200626144A (es)
WO (1) WO2006060532A2 (es)
ZA (1) ZA200705011B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052681A1 (es) * 2005-03-08 2007-03-28 Wyeth Corp Formas cristalinas de 2-(3-fluoro-4 hidroxifenil ) -7 -vinil-1,3- benzoxazol -5-ol
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands
TW200803850A (en) * 2006-03-06 2008-01-16 Wyeth Corp Tablet formulations and processes
TW200800179A (en) * 2006-03-06 2008-01-01 Wyeth Corp Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
TW200800180A (en) * 2006-03-06 2008-01-01 Wyeth Corp Liquid and semi-solid pharmaceutical formulations and processes
WO2007103877A2 (en) * 2006-03-06 2007-09-13 Wyeth Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP1499391A2 (en) * 2002-04-10 2005-01-26 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant

Also Published As

Publication number Publication date
EP1850833A2 (en) 2007-11-07
NO20072636L (no) 2007-08-13
KR20070089921A (ko) 2007-09-04
AR053653A1 (es) 2007-05-16
PE20061083A1 (es) 2006-11-14
TW200626144A (en) 2006-08-01
RU2007120253A (ru) 2009-01-10
GT200500349A (es) 2006-07-03
WO2006060532A2 (en) 2006-06-08
US20060121110A1 (en) 2006-06-08
BRPI0518786A2 (pt) 2008-12-09
CN101128188A (zh) 2008-02-20
MX2007006564A (es) 2007-06-19
CA2589033A1 (en) 2006-06-08
SV2006002317A (es) 2006-06-26
AU2005311823A1 (en) 2006-06-08
ZA200705011B (en) 2010-01-27
NZ555395A (en) 2009-07-31
NI200700139A (es) 2008-05-09
IL183393A0 (en) 2007-09-20
WO2006060532A3 (en) 2006-11-16
JP2008521919A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
CY2022001I1 (el) Παραγωγα του uk-2a
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
DK1720866T3 (da) Fremgangsmåde
EP2046290A4 (en) AQUEOUS DRONABINOL FORMULATIONS
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
DK1802579T3 (da) Derivater af 3-arylaminopyridin
ITMI20050191A1 (it) Struttura di fet ad alette
EP1751652A4 (en) MONITOR DEVICE
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
EP1968937A4 (en) DEAZAPURINANALOGA OF 1-AZA-L-NUCLEOSIDES
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
BRPI0715621A2 (pt) Formulações galênicas de compostos orgânicos
PT1850664E (pt) Formulação de cápsulas
ZA200705011B (en) Formulations of substituted benzoxazoles
DK1954241T3 (da) Zonisamid-formulering med vedvarende frigivelse
DE602005008726D1 (de) Verwendet
IS8309A (is) Lyfjablöndur
NO20043305D0 (no) Preparation of lodixanol
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
ATE551899T1 (de) Feststoff-formulierung fungizider mischungen
PL1843746T3 (pl) Formulacje analogów somatostatyny
NO20055643D0 (no) Preparation of lodixanol
EP1906944A4 (en) SKI ANDRIN-B-PREPARATION
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)